Funding of Parkinson research from industry and US federal and foundation sources
Identifieur interne : 000400 ( Main/Corpus ); précédent : 000399; suivant : 000401Funding of Parkinson research from industry and US federal and foundation sources
Auteurs : E. Ray Dorsey ; Joel P. Thompson ; Mark Frasier ; Todd Sherer ; Brian Fiske ; Sean Nicholson ; S. Claiborne Johnston ; Robert G. Holloway ; Hamilton Moses IiiSource :
- Movement Disorders [ 0885-3185 ] ; 2009-04-15.
English descriptors
Abstract
Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22446
Links to Exploration step
ISTEX:98702278CB3FFAF8078BAEDBF281805103A0D553Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Funding of Parkinson research from industry and US federal and foundation sources</title><author><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name><affiliation><mods:affiliation>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences, Buffalo, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name><affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name><affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name><affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name><affiliation><mods:affiliation>Department of Policy Analysis and Management, Cornell University, Ithaca, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Johnston, S Claiborne" sort="Johnston, S Claiborne" uniqKey="Johnston S" first="S. Claiborne" last="Johnston">S. Claiborne Johnston</name><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Moses Iii, Hamilton" sort="Moses Iii, Hamilton" uniqKey="Moses Iii H" first="Hamilton" last="Moses Iii">Hamilton Moses Iii</name><affiliation><mods:affiliation>The Alerion Institute, North Garden, Virginia, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:98702278CB3FFAF8078BAEDBF281805103A0D553</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22446</idno><idno type="url">https://api.istex.fr/document/98702278CB3FFAF8078BAEDBF281805103A0D553/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000400</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Funding of Parkinson research from industry and US federal and foundation sources</title><author><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name><affiliation><mods:affiliation>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences, Buffalo, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name><affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name><affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name><affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name><affiliation><mods:affiliation>Department of Policy Analysis and Management, Cornell University, Ithaca, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Johnston, S Claiborne" sort="Johnston, S Claiborne" uniqKey="Johnston S" first="S. Claiborne" last="Johnston">S. Claiborne Johnston</name><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Moses Iii, Hamilton" sort="Moses Iii, Hamilton" uniqKey="Moses Iii H" first="Hamilton" last="Moses Iii">Hamilton Moses Iii</name><affiliation><mods:affiliation>The Alerion Institute, North Garden, Virginia, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-15">2009-04-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="731">731</biblScope><biblScope unit="page" to="737">737</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">98702278CB3FFAF8078BAEDBF281805103A0D553</idno><idno type="DOI">10.1002/mds.22446</idno><idno type="ArticleID">MDS22446</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson disease</term><term>biomedical research</term><term>drug development</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>E. Ray Dorsey MD, MBA</name><affiliations><json:string>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Joel P. Thompson MPH</name><affiliations><json:string>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences, Buffalo, New York, USA</json:string></affiliations></json:item><json:item><name>Mark Frasier PhD</name><affiliations><json:string>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Todd Sherer PhD</name><affiliations><json:string>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Brian Fiske PhD</name><affiliations><json:string>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Sean Nicholson PhD</name><affiliations><json:string>Department of Policy Analysis and Management, Cornell University, Ithaca, New York, USA</json:string></affiliations></json:item><json:item><name>S. Claiborne Johnston MD, PhD</name><affiliations><json:string>Department of Neurology, University of California, San Francisco, California, USA</json:string></affiliations></json:item><json:item><name>Robert G. Holloway MD, MPH</name><affiliations><json:string>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Hamilton Moses III MD</name><affiliations><json:string>The Alerion Institute, North Garden, Virginia, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>biomedical research</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>drug development</value></json:item></subject><articleId><json:string>MDS22446</json:string></articleId><language><json:string>eng</json:string></language><abstract>Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>6.178</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1211</abstractCharCount><pdfWordCount>3814</pdfWordCount><pdfCharCount>25007</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>197</abstractWordCount></qualityIndicators><title>Funding of Parkinson research from industry and US federal and foundation sources</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>737</last><first>731</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22446</json:string></doi><id>98702278CB3FFAF8078BAEDBF281805103A0D553</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/98702278CB3FFAF8078BAEDBF281805103A0D553/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/98702278CB3FFAF8078BAEDBF281805103A0D553/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/98702278CB3FFAF8078BAEDBF281805103A0D553/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Funding of Parkinson research from industry and US federal and foundation sources</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*The views expressed in the article reflect those of the authors alone and do not necessarily reflect those of any funding organization.</note><note type="content">*Potential conflict of interest: The Michael J. Fox Foundation supported this research. Drs. Frasier, Fiske, and Sherer, Co‐authors of the manuscript, are employees of the Michael J. Fox Foundation. Dr. Dorsey holds stock options in Avid Radiopharmaceuticals, Inc., which had no role in this manuscript.</note><note>Michael J. Fox Foundation for Parkinson's Research</note><note>Mr. Robin Anthony Elliott from the Parkinson's Disease Foundation</note><note>Mr. Joel Gerstel from the American Parkinson Disease Association</note><note>Ms. Pamela Olmo from the National Parkinson Foundation</note><note>National Institute of Neurological Disorders and Stroke - No. K24 NS4 2098;</note><note>National Center for Research Resources (NCRR) - No. 1 UL1 RR024160‐01;</note><note>National Institutes of Health (NIH)</note><note>NIH Roadmap for Medical Research</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Funding of Parkinson research from industry and US federal and foundation sources</title><author><persName><forename type="first">E. Ray</forename><surname>Dorsey</surname></persName><roleName type="degree">MD, MBA</roleName><note type="correspondence"><p>Correspondence: 1351 Mt. Hope Ave., Suite 223, Rochester, New York 14620</p></note><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Joel P.</forename><surname>Thompson</surname></persName><roleName type="degree">MPH</roleName><affiliation>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences, Buffalo, New York, USA</affiliation></author><author><persName><forename type="first">Mark</forename><surname>Frasier</surname></persName><roleName type="degree">PhD</roleName><affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</affiliation></author><author><persName><forename type="first">Todd</forename><surname>Sherer</surname></persName><roleName type="degree">PhD</roleName><affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</affiliation></author><author><persName><forename type="first">Brian</forename><surname>Fiske</surname></persName><roleName type="degree">PhD</roleName><affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</affiliation></author><author><persName><forename type="first">Sean</forename><surname>Nicholson</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Policy Analysis and Management, Cornell University, Ithaca, New York, USA</affiliation></author><author><persName><forename type="first">S. Claiborne</forename><surname>Johnston</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, University of California, San Francisco, California, USA</affiliation></author><author><persName><forename type="first">Robert G.</forename><surname>Holloway</surname></persName><roleName type="degree">MD, MPH</roleName><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Hamilton</forename><surname>Moses III</surname></persName><roleName type="degree">MD</roleName><affiliation>The Alerion Institute, North Garden, Virginia, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-15"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="731">731</biblScope><biblScope unit="page" to="737">737</biblScope></imprint></monogr><idno type="istex">98702278CB3FFAF8078BAEDBF281805103A0D553</idno><idno type="DOI">10.1002/mds.22446</idno><idno type="ArticleID">MDS22446</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson disease</term></item><item><term>biomedical research</term></item><item><term>drug development</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-05-15">Received</change><change when="2008-12-02">Registration</change><change when="2009-04-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/98702278CB3FFAF8078BAEDBF281805103A0D553/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/mds.v24:5</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2009-04-15">15 April 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="150" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22446</doi><idGroup><id type="unit" value="MDS22446"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-05-15"></event><event type="manuscriptRevised" date="2008-09-11"></event><event type="manuscriptAccepted" date="2008-12-02"></event><event type="publishedOnlineEarlyUnpaginated" date="2009-01-09"></event><event type="firstOnline" date="2009-01-09"></event><event type="publishedOnlineFinalForm" date="2009-04-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">731</numbering><numbering type="pageLast">737</numbering></numberingGroup><correspondenceTo>1351 Mt. Hope Ave., Suite 223, Rochester, New York 14620</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22446.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="36"></count><count type="wordTotal" number="4563"></count></countGroup><titleGroup><title type="main" xml:lang="en">Funding of Parkinson research from industry and US federal and foundation sources<link href="#fn2"></link> <link href="#fn3"></link></title><title type="short" xml:lang="en">Funding of Parkinson Research</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>E. Ray</givenNames><familyName>Dorsey</familyName><degrees>MD, MBA</degrees></personName><contactDetails><email>ray.dorsey@ctcc.rochester.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Joel P.</givenNames><familyName>Thompson</familyName><degrees>MPH</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Mark</givenNames><familyName>Frasier</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Todd</givenNames><familyName>Sherer</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Brian</givenNames><familyName>Fiske</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Sean</givenNames><familyName>Nicholson</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af5"><personName><givenNames>S. Claiborne</givenNames><familyName>Johnston</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Robert G.</givenNames><familyName>Holloway</familyName><degrees>MD, MPH</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Hamilton</givenNames><familyName>Moses</familyName><nameSuffix>III</nameSuffix><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences, Buffalo, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Policy Analysis and Management, Cornell University, Ithaca, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of California, San Francisco, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>The Alerion Institute, North Garden, Virginia, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson disease</keyword><keyword xml:id="kwd2">biomedical research</keyword><keyword xml:id="kwd3">drug development</keyword></keywordGroup><fundingInfo><fundingAgency>Michael J. Fox Foundation for Parkinson's Research</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Mr. Robin Anthony Elliott from the Parkinson's Disease Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Mr. Joel Gerstel from the American Parkinson Disease Association</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Ms. Pamela Olmo from the National Parkinson Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>National Institute of Neurological Disorders and Stroke</fundingAgency><fundingNumber>K24 NS4 2098</fundingNumber></fundingInfo><fundingInfo><fundingAgency>National Center for Research Resources (NCRR)</fundingAgency><fundingNumber>1 UL1 RR024160‐01</fundingNumber></fundingInfo><fundingInfo><fundingAgency>National Institutes of Health (NIH)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>NIH Roadmap for Medical Research</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn2"><p>The views expressed in the article reflect those of the authors alone and do not necessarily reflect those of any funding organization.</p></note><note xml:id="fn3"><p>Potential conflict of interest: The Michael J. Fox Foundation supported this research. Drs. Frasier, Fiske, and Sherer, Co‐authors of the manuscript, are employees of the Michael J. Fox Foundation. Dr. Dorsey holds stock options in Avid Radiopharmaceuticals, Inc., which had no role in this manuscript.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Funding of Parkinson research from industry and US federal and foundation sources</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Funding of Parkinson Research</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Funding of Parkinson research from industry and US federal and foundation sources</title></titleInfo><name type="personal"><namePart type="given">E. Ray</namePart><namePart type="family">Dorsey</namePart><namePart type="termsOfAddress">MD, MBA</namePart><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><description>Correspondence: 1351 Mt. Hope Ave., Suite 223, Rochester, New York 14620</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joel P.</namePart><namePart type="family">Thompson</namePart><namePart type="termsOfAddress">MPH</namePart><affiliation>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences, Buffalo, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark</namePart><namePart type="family">Frasier</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Todd</namePart><namePart type="family">Sherer</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Brian</namePart><namePart type="family">Fiske</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sean</namePart><namePart type="family">Nicholson</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Policy Analysis and Management, Cornell University, Ithaca, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. Claiborne</namePart><namePart type="family">Johnston</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University of California, San Francisco, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert G.</namePart><namePart type="family">Holloway</namePart><namePart type="termsOfAddress">MD, MPH</namePart><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hamilton</namePart><namePart type="family">Moses III</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Alerion Institute, North Garden, Virginia, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-04-15</dateIssued><dateCaptured encoding="w3cdtf">2008-05-15</dateCaptured><dateValid encoding="w3cdtf">2008-12-02</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">2</extent><extent unit="references">36</extent><extent unit="words">4563</extent></physicalDescription><abstract lang="en">Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies. © 2009 Movement Disorder Society</abstract><note type="content">*The views expressed in the article reflect those of the authors alone and do not necessarily reflect those of any funding organization.</note><note type="content">*Potential conflict of interest: The Michael J. Fox Foundation supported this research. Drs. Frasier, Fiske, and Sherer, Co‐authors of the manuscript, are employees of the Michael J. Fox Foundation. Dr. Dorsey holds stock options in Avid Radiopharmaceuticals, Inc., which had no role in this manuscript.</note><note type="funding">Michael J. Fox Foundation for Parkinson's Research</note><note type="funding">Mr. Robin Anthony Elliott from the Parkinson's Disease Foundation</note><note type="funding">Mr. Joel Gerstel from the American Parkinson Disease Association</note><note type="funding">Ms. Pamela Olmo from the National Parkinson Foundation</note><note type="funding">National Institute of Neurological Disorders and Stroke - No. K24 NS4 2098; </note><note type="funding">National Center for Research Resources (NCRR) - No. 1 UL1 RR024160‐01; </note><note type="funding">National Institutes of Health (NIH)</note><note type="funding">NIH Roadmap for Medical Research</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson disease</topic><topic>biomedical research</topic><topic>drug development</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>731</start><end>737</end><total>7</total></extent></part></relatedItem><identifier type="istex">98702278CB3FFAF8078BAEDBF281805103A0D553</identifier><identifier type="DOI">10.1002/mds.22446</identifier><identifier type="ArticleID">MDS22446</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000400 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000400 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:98702278CB3FFAF8078BAEDBF281805103A0D553
|texte= Funding of Parkinson research from industry and US federal and foundation sources
}}
| This area was generated with Dilib version V0.6.23. |  |